CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, has a couple of clinical trial events to watch in the coming months.
The lead compound is Auxora, a potent and selective small molecule calcium release activated calcium (CRAC) channel inhibitor. CRAC channels may become hyperactive in specific tissues as a consequence of infection, trauma, or exposure to toxins, leading to cellular damage and death, contributing to a range of diseases.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.